Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,999

Document Document Title
WO/2019/008555A1
The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-...  
WO/2019/007418A1
The present invention relates to the technical field of pharmacy, and specifically relates to a compound as represented by formula (I), and a pharmaceutically acceptable salt, an ester or stereoisomers thereof. R1, X1, X2, M, Ar, ring A,...  
WO/2019/008152A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-l/PD-Ll protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/008141A1
The present invention provides a phenothiazine derivative of formula (I) for use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as N.meningitidis,and more specifically for use in preventing and/or ...  
WO/2019/003143A1
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. F...  
WO/2019/006359A1
The present disclosure relates to compounds that are capable of inhibiting the mitochondrial pyruvate carrier and promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorde...  
WO/2019/001307A1
An amide compound of formula (I), a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotope variant, a hydrate, or a solvate thereof, a pharmaceutical composition containing the compound, and a pharmaceutical...  
WO/2019/001396A1
Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), ...  
WO/2019/000494A1
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...  
WO/2019/006126A1
Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and composition...  
WO/2019/002074A1
The present invention provides PRMT5 inhibiting compounds of general formula (I). A compound of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, L1 and L2 are as defined herein, methods of preparing said compounds, intermediate ...  
WO/2019/001416A1
The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in...  
WO/2019/004464A1
The purpose of the present invention is to provide a composition for inhibiting the proliferation and/or infiltration of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression associated ...  
WO/2019/001420A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2019/000683A1
Provided are a Rho-associated protein kinase (ROCK) inhibitor of formula (I), a pharmaceutical composition containing said Rho-associated protein kinase inhibitor, a preparation method thereof and an application of the ROCK for treating ...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  
WO/2018/234808A1
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/234805A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/234343A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/234807A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)  
WO/2018/235813A1
A compound represented by the formula, which has an RORγt inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.  
WO/2018/235549A1
The present invention provides a composition which is capable of forming a film having a high refractive index and which has excellent conformability to level differences. Moreover, the present invention provides a film obtained using th...  
WO/2018/234240A1
Compounds of formula (I), as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and co...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/229193A1
The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tauto...  
WO/2018/229511A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic and M4 receptors. Also provided are pharmaceutical compositions co...  
WO/2018/229197A1
The present invention relates to bicyclic heteroaromatic urea or carbamate compounds of formula I where the variables are as defined in the claims and the description. The invention moreover relates to a pharmaceutical composition contai...  
WO/2018/228446A1
The present invention relates to an aminopyrimidine compound, a preparation method therefor and the use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth fa...  
WO/2018/231634A1
The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or...  
WO/2018/229194A1
The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing ...  
WO/2018/229195A1
The present invention relates to compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing such compounds; and to said compounds of the formula I...  
WO/2018/228275A1
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing same, and a preparation method therefor, as well as an application of the heterocyclic compound as mitogen-activated protein kinase interac...  
WO/2018/228435A1
A compound as a GLS1 inhibitor as represented by formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2018/226542A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of c-Met and/or p38 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von ...  
WO/2018/223876A1
Provided are a fluorescent probe, a preparation method and application thereof. The fluorescent probe is an addition-activation probe and can be used for specific fluorescent protein labeling, and can also be used for protein quantificat...  
WO/2018/227067A1
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2018/227023A1
Various compositions are disclosed. The compositions of composition-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and uses of the composition-immune stimulatory compound co...  
WO/2018/225999A1
The present specification provides a compound comprising units of formula 1 and an organic solar cell comprising the same.  
WO/2018/220533A2
Provided is a method for producing an optically active pyrimidine amide derivative that can be produced on an industrial scale. Compound (I), (V) or a salt thereof is subjected to an asymmetric reduction reaction, the obtained compound (...  
WO/2018/222795A1
Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are metho...  
WO/2018/221720A1
The present invention provides: a heterocyclic compound and an intermediate thereof, the compound having an excellent controlling effect against harmful arthropods and being represented by formula (I) (in the formula, R2 represents a C1-...  
WO/2018/219825A1
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/220149A1
The present invention provides compounds which are selective allosteric inhibitors of TMLR, TMLRCS, LR, LRCS containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active ...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/214959A1
Disclosed is a compound as shown in formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and the present invention relates to the use of same in the preparation of a drug for treating FXR-related diseases.  
WO/2018/214867A1
An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (1), a preparation method therefor, and a use thereof, each substituent being defined in the description and claims. The compound can be widely applied to t...  
WO/2018/218044A2
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenera...  
WO/2018/218070A2
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b...  
WO/2018/216823A1
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...  

Matches 1 - 50 out of 36,999